Distinct structure and activity of monoamine oxidase in the brain of zebrafish (Danio rerio)

被引:72
作者
Anichtchik, Oleg
Sallinen, Ville
Peitsaro, Nina
Panula, Pertti
机构
[1] Univ Helsinki, Biomedicum Helsinki, Inst Biomed Anat, Ctr Neurosci, Helsinki 00290, Finland
[2] Abo Akad Univ, Dept Biol, Turku 20250, Finland
关键词
catecholamines; dopamine; histamine; histochemistry; MPTP; Parkinson's disease;
D O I
10.1002/cne.21057
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Monoamine oxidase (MAO) is a mitochondrial flavoprotein involved in the metabolism of, e.g., aminergic neurotransmitters and the parkinsonism-inducing neurotoxin 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP). We have reported earlier MPTP-related alterations of brain catecholaminergic system in zebrafish (Danio rerio) brain. Here we describe the structural and functional properties of zebrafish NUO and the distribution of MAO mRNA and activity in zebrafish brain. The gene is located in chromosome 9 and consists of 15 exons. The amino acid composition of the active center resembles both human MAO-A and MAO-B. The enzyme displayed the highest substrate specificity for tyramine, followed by serotonin, phenylethylamine, MPTP, and dopamine; isoform-specific antagonists blocked the activity of the enzyme with equal potency. Zebrafish NIAO mRNA, which was present in several tissues, and enzyme displayed differential distribution in the brain; dopaminergic cell clusters had low to moderate levels of MAO activity, whereas the highest levels of MAO activity were detected in noradrenergic and serotonergic cell groups and the habenulointerpeduncular pathway, including its caudal projection to the medial ventral rhombencephalon. The results of this study confirm the presence of functionally active MAO in zebrafish brain and other tissues and characterize the neural systems that express NUO and areas of intense activity in the brain. They also suggest that MPTP toxicity not related to MAO may affect the zebrafish brain.
引用
收藏
页码:593 / 610
页数:18
相关论文
共 45 条
[1]   L-DEPRENYL CONFERS SPECIFIC PROTECTION AGAINST MPTP-INDUCED PARKINSONS DISEASE-LIKE MOVEMENT DISORDER IN THE GOLDFISH [J].
ADEYEMO, OM ;
YOUDIM, MBH ;
MARKEY, SP ;
MARKEY, CJ ;
POLLARD, HB .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1993, 240 (2-3) :185-193
[2]  
ANICHTCHIK O, 2004, 16418 SOC NEUR
[3]   Neurochemical and behavioural changes in zebrafish Danio rerio after systemic administration of 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine [J].
Anichtchik, OV ;
Kaslin, J ;
Peitsaro, N ;
Scheinin, M ;
Panula, P .
JOURNAL OF NEUROCHEMISTRY, 2004, 88 (02) :443-453
[4]   MULTIPLE FORMS MONOAMINE OXIDASE IN DEVELOPING XENOPUS [J].
BAKER, PC .
EXPERIENTIA, 1971, 27 (03) :245-&
[5]   Structure of human monoamine oxidase B, a drug target for the treatment of neurological disorders [J].
Binda, C ;
Newton-Vinson, P ;
Hubálek, F ;
Edmondson, DE ;
Mattevi, A .
NATURE STRUCTURAL BIOLOGY, 2002, 9 (01) :22-26
[6]  
CHEN K, 1994, MOL PHARMACOL, V46, P1226
[7]   Does monoamine oxidase type B play a role in dopaminergic nerve cell death in Parkinson's disease? [J].
Damier, P ;
Kastner, A ;
Agid, Y ;
Hirsch, EC .
NEUROLOGY, 1996, 46 (05) :1262-1269
[8]  
DEMAREST KT, 1980, J PHARMACOL EXP THER, V215, P461
[9]  
Driever W, 1996, DEVELOPMENT, V123, P37
[10]   Catecholamine metabolism: A contemporary view with implications for physiology and medicine [J].
Eisenhofer, G ;
Kopin, IJ ;
Goldstein, DS .
PHARMACOLOGICAL REVIEWS, 2004, 56 (03) :331-349